TG Therapeutics Reported Over 900 Briumvi (Indicated For Relapsing Forms Of Multiple Sclerosis ) Prescriptions In Q3 FY23, Marking Approximately 2,200 Prescriptions Since Launch (January), From Over 500 Healthcare Providers At Over 250 Centers
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics reported over 900 prescriptions for Briumvi, indicated for relapsing forms of Multiple Sclerosis, in Q3 FY23. This marks approximately 2,200 prescriptions since its launch in January, from over 500 healthcare providers at over 250 centers.
November 01, 2023 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics' Briumvi has seen strong prescription growth since its launch, indicating positive market acceptance and potential revenue growth.
The reported increase in prescriptions for Briumvi indicates a positive market response to the drug. This could lead to increased revenues for TG Therapeutics, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100